Noncirrhotic presinusoidal portal hypert
β
Peter Witters; Louis Libbrecht; Tania Roskams; Kris De Boeck; Lieven Dupont; Mar
π
Article
π
2011
π
John Wiley and Sons
π
English
β 632 KB
Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.